229 related articles for article (PubMed ID: 10421398)
1. Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B.
Oketani M; Oketani K; Xiaohong C; Arima T
J Med Virol; 1999 Aug; 58(4):332-7. PubMed ID: 10421398
[TBL] [Abstract][Full Text] [Related]
2. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels.
Cabrerizo M; Bartolomé J; Iñigo ER; López-Alcorocho JM; Cotonat T; Carreño V
J Med Virol; 1998 Dec; 56(4):294-9. PubMed ID: 9829632
[TBL] [Abstract][Full Text] [Related]
5. [The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection].
Kim HJ; Yoo BC
Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):149-56. PubMed ID: 12499800
[TBL] [Abstract][Full Text] [Related]
6. Low level hepatitis B viremia detected by polymerase chain reaction accompanies the absence of HBe antigenemia and hepatitis in hepatitis B virus carriers.
Niitsuma H; Ishii M; Miura M; Kobayashi K; Toyota T
Am J Gastroenterol; 1997 Jan; 92(1):119-23. PubMed ID: 8995950
[TBL] [Abstract][Full Text] [Related]
7. Emergence of the precore mutant late in chronic hepatitis B infection correlates with the severity of liver injury and mutations in the core region.
Maruyama T; Mitsui H; Maekawa H; Yamada H; Hirayama M; Iino S; Yasuda K; Koike K; Kimura S; Milich DR
Am J Gastroenterol; 2000 Oct; 95(10):2894-904. PubMed ID: 11051365
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
[TBL] [Abstract][Full Text] [Related]
9. Response of pre-core mutant chronic hepatitis B infection to lamivudine.
Rizzetto M; Volpes R; Smedile A
J Med Virol; 2000 Jul; 61(3):398-402. PubMed ID: 10861653
[TBL] [Abstract][Full Text] [Related]
10. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.
Manesis EK; Papatheodoridis GV; Sevastianos V; Cholongitas E; Papaioannou C; Hadziyannis SJ
Am J Gastroenterol; 2003 Oct; 98(10):2261-7. PubMed ID: 14572577
[TBL] [Abstract][Full Text] [Related]
11. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase.
Chu CM; Chen YC; Tai DI; Liaw YF
Clin Gastroenterol Hepatol; 2010 Jun; 8(6):535-40. PubMed ID: 20304099
[TBL] [Abstract][Full Text] [Related]
12. Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B.
Yuen MF; Ng IO; Fan ST; Yuan HJ; Wong DK; Yuen JC; Sum SS; Chan AO; Lai CL
Am J Gastroenterol; 2004 Oct; 99(10):2032-7. PubMed ID: 15447768
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus genotypes and precore/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection.
Ayed K; Gorgi Y; Ayed-Jendoubi S; Aouadi H; Sfar I; Najjar T; Ben Abdallah T
J Infect; 2007 Mar; 54(3):291-7. PubMed ID: 16911832
[TBL] [Abstract][Full Text] [Related]
14. Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission.
Zampino R; Marrone A; Karayiannis P; Cirillo G; del Giudice EM; Rania G; Utili R; Ruggiero G
Am J Gastroenterol; 2002 Sep; 97(9):2426-31. PubMed ID: 12358268
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
17. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.
Ferns RB; Naoumov NV; Gilson RJ; Tedder RS
J Clin Virol; 2007 Jul; 39(3):199-204. PubMed ID: 17526429
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients.
Kumar M; Chauhan R; Gupta N; Hissar S; Sakhuja P; Sarin SK
Gastroenterology; 2009 Apr; 136(4):1272-80. PubMed ID: 19208347
[TBL] [Abstract][Full Text] [Related]
19. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
Bozkaya H; Yurdaydin C; Idilman R; Tüzün A; Cinar K; Erkan O; Bozdayi AM; Erden E; Uzun Y; Cetinkaya H; Uzunalimoglu O
Antivir Ther; 2005; 10(2):319-25. PubMed ID: 15865226
[TBL] [Abstract][Full Text] [Related]
20. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
